FDA warning letters drop as audit preparation increases
Warning letters issued to investigators by the FDA’s Center for Drug Evaluation and Research (CDER) have dropped 13% (annualized) during the past five years as the industry has strengthened efforts to ensure sites comply with regulatory requirements that safeguard data integrity and human subject protection in clinical trials.
Still an underutilized resource, medical science liaisons can serve as a bridge between science, economics. Originally hired by sponsors to perform outreach with payers and providers while their drugs were awaiting FDA approval, MSLs have seen their role evolve dramatically over time into more of a global pharmacological resource who can present data in a fair and clear way for the improvement and benefit of patients and the overall public health sector.
To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.